MX2019006296A - Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. - Google Patents

Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.

Info

Publication number
MX2019006296A
MX2019006296A MX2019006296A MX2019006296A MX2019006296A MX 2019006296 A MX2019006296 A MX 2019006296A MX 2019006296 A MX2019006296 A MX 2019006296A MX 2019006296 A MX2019006296 A MX 2019006296A MX 2019006296 A MX2019006296 A MX 2019006296A
Authority
MX
Mexico
Prior art keywords
methods
compounds
pyrazole
treatment
hyperproliferative diseases
Prior art date
Application number
MX2019006296A
Other languages
English (en)
Inventor
Ciblat Stephane
Grand-Maitre Chantal
Srivastava Sanjay
W Shipps Gerald
M Siddiqui Arshad
CONSTANTINEUA-FORGET Lea
B Cooper Alan
Oza Vibha
Luther Michael
Levine Jedd
Guo Xiangyu Jr
Kostura Matthew
Original Assignee
Bantam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bantam Pharmaceutical Llc filed Critical Bantam Pharmaceutical Llc
Publication of MX2019006296A publication Critical patent/MX2019006296A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen metodos para tratar trastornos hiperproliferativos, tales como cáncer, metodos para detener el ciclo celular en celulas cancerosas, metodos para inhibir la síntesis de glutation en celulas cancerosas, y compuestos asociados para usar, asi como usos en medicamentos, en ciertas formas de realización, los metodos, usos y compuestos se proporcionan en referencia a compuestos de la formula estructural (I),(ver formula) en donde X1, X2, Z1, Z2, el sistema de anillos indicado con "a", R1, L1, L2, Q, L3, R3, L4, R4, L5, y R5 son como se describen en la presente. En ciertas formas de realización, los compuestos descritos en la presente son especialmente activos contra tipos de cáncer que tienen un gen KRAS mutante.
MX2019006296A 2016-11-30 2017-11-29 Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas. MX2019006296A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428274P 2016-11-30 2016-11-30
PCT/US2017/063772 WO2018102452A2 (en) 2016-11-30 2017-11-29 Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases

Publications (1)

Publication Number Publication Date
MX2019006296A true MX2019006296A (es) 2019-11-12

Family

ID=62242614

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006296A MX2019006296A (es) 2016-11-30 2017-11-29 Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.

Country Status (9)

Country Link
US (1) US20200069656A1 (es)
EP (1) EP3548024A2 (es)
JP (1) JP2020513403A (es)
CN (1) CN110769823A (es)
BR (1) BR112019011035A2 (es)
CA (1) CA3082011A1 (es)
IL (1) IL266931A (es)
MX (1) MX2019006296A (es)
WO (1) WO2018102452A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
BR112019011044A2 (pt) * 2016-11-30 2019-10-08 Bantam Pharmaceutical Llc compostos pirazol substituídos e métodos de uso no tratamento de doenças hiperproliferativas
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
AU2018369759B2 (en) 2017-11-15 2022-11-24 Array Biopharma Inc. KRas G12C inhibitors
EP3790551A4 (en) 2018-05-07 2022-03-09 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
EP3976605A1 (en) * 2019-05-31 2022-04-06 Bantam Pharmaceutical, LLC Methods for making thiszolylpyrazole carboxylic acids and intermediates therefor
CA3142196A1 (en) 2019-05-31 2020-12-03 Bantam Pharmaceutical, Llc Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative
JP2022546043A (ja) 2019-08-29 2022-11-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｄ阻害剤
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
CN115135315A (zh) 2019-12-20 2022-09-30 米拉蒂治疗股份有限公司 Sos1抑制剂
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008121861A2 (en) * 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
WO2009123316A1 (ja) * 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
SI2275414T1 (sl) * 2008-04-28 2015-10-30 Kyorin Pharmaceutical Co., Ltd., Ciklopentilakrilamidni derivat
EP3286187B1 (en) * 2015-04-24 2019-09-18 Syngenta Participations AG Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
CN108349962A (zh) * 2015-06-01 2018-07-31 班塔姆制药有限责任公司 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法

Also Published As

Publication number Publication date
CA3082011A1 (en) 2018-06-07
WO2018102452A2 (en) 2018-06-07
EP3548024A2 (en) 2019-10-09
CN110769823A (zh) 2020-02-07
IL266931A (en) 2019-07-31
WO2018102452A3 (en) 2020-07-09
BR112019011035A2 (pt) 2019-10-15
US20200069656A1 (en) 2020-03-05
JP2020513403A (ja) 2020-05-14

Similar Documents

Publication Publication Date Title
MX2019006296A (es) Métodos de uso de compuestos de pirazol y pirazol sustituido y para el tratamiento de enfermedades hiperproliferativas.
MX2019006299A (es) Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
PH12017502246B1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017502407A1 (en) Fused pyrimidine compound or salt thereof
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
NZ738471A (en) New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
TW201613593A (en) Molecules for administration to ROS1 mutant cancer cells
PH12018500605A1 (en) New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
GEP20227434B (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
MX2013010898A (es) Novedoso derivados de la pirimidina.
AU2018253590A1 (en) Imidazopyridazine compounds
MX356644B (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
TN2019000204A1 (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
TW201613864A (en) Novel compounds
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
AU2019257509A1 (en) Androgen receptor modulators and methods for their use
WO2015042414A8 (en) Multicyclic compounds and methods of using same
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil